Welcome to our dedicated page for HealWELL AI news (Ticker: HWAIF), a resource for investors and traders seeking the latest updates and insights on HealWELL AI stock.
HEALWELL AI Inc. (OTCQX: HWAIF; TSX: AIDX) regularly issues news updates as a healthcare artificial intelligence company focused on preventative care and early disease detection. Its announcements describe how the company is developing and commercializing proprietary clinical decision support systems and AI platforms intended to help healthcare providers detect rare and chronic diseases, improve efficiency, and support better patient outcomes.
News releases from HEALWELL cover a range of topics, including financial and operational updates, strategic acquisitions and divestments, and progress in integrating acquired businesses such as Orion Health. The company has reported a transition toward a pure-play digital SaaS, services and AI business focused on health systems and large enterprise customers, and its news flow reflects this emphasis on enterprise-grade healthcare software and data science offerings.
HEALWELL’s news also highlights developments in its AI platforms, including the DARWEN™ AI system and the launch of AmadeusAI, an AI-enabled digital care record built on Orion Health’s Amadeus platform. Announcements have described new AI tools such as SMARTSearch, SMARTSummary, and SMARTIdentify, as well as collaborations with public health organizations, healthcare systems, and life sciences partners.
Investors and observers can use this news page to follow HEALWELL’s disclosures on corporate transactions, joint ventures, memoranda of understanding, recognition of its AI technologies in peer-reviewed studies, and participation in industry and investment conferences. The updates provide context on how the company presents its strategy in preventative healthcare AI, its focus on real-world data and evidence generation, and its orientation toward large-scale health system and enterprise deployments.
WELL Health Technologies and HEALWELL AI have expanded their multi-year strategic alliance to launch and manage clinical trial sites across WELL's network of over 180 Canadian clinics. The partnership combines WELL's healthcare infrastructure with HEALWELL's AI technology and Contract Research Organization capabilities to create an end-to-end clinical trials service. The collaboration will leverage WELL's extensive network of primary and specialty care clinics, including diagnostic centers specializing in cardiology, radiology, sleep medicine, and endocrinology, to enhance patient recruitment and trial execution while opening new revenue streams.
WELL Health Technologies and HEALWELL AI have expanded their multi-year strategic alliance to launch and manage clinical trial sites across WELL's network of over 180 Canadian clinics. The partnership combines WELL's extensive healthcare infrastructure with HEALWELL's AI and Contract Research Organization capabilities to create an end-to-end clinical trials service. The collaboration will leverage WELL's primary and specialty care network, including cardiology, radiology, sleep medicine, and endocrinology departments, to enhance patient recruitment and trial execution while opening new revenue streams. This initiative aims to improve patient access to experimental treatments and transform WELL's clinics into innovation hubs.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) has announced a strategic investment of USD$250,000 in Abstractive Health, a healthcare AI company specializing in automated patient summaries using proprietary generative AI technology. The investment is part of a broader funding round led by Rho Capital Partners. Concurrent with the investment, HEALWELL has entered into a commercial agreement with Abstractive Health, securing exclusive distribution rights for the Canadian outpatient healthcare market.
Abstractive Health's AI software leverages LLMs and generative AI to automate medical record summaries, streamlining healthcare documentation processes. HEALWELL plans to integrate Abstractive Health's technology into WELL Health Technologies' apps.health marketplace, expanding its suite of AI-enabled co-pilot technologies for healthcare providers.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), a healthcare technology company focused on AI and data science for preventative care, announces its participation in the 17th Annual LD Micro Main Event from October 28-30th, 2024, at the Luxe Sunset Boulevard Hotel in Los Angeles. Dr. Alexander Dobranowski, CEO of HEALWELL, will deliver a live presentation on Wednesday, October 30, 2024, at 10:30am PT and conduct in-person meetings.
Dr. Dobranowski expressed enthusiasm about sharing HEALWELL's story and showcasing their AI-driven clinical decision support systems. The event provides an opportunity to update existing shareholders and introduce the company to potential new U.S. investors. Chris Lahiji, Founder of LD Micro, emphasized the event's significance in the small and micro-cap industry.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, will participate in the 2024 Cantech Letter Investment Conference on October 9, 2024, in Toronto, Ontario. Dr. Alexander Dobranowski, CEO of HEALWELL, will deliver an investor presentation at 10:00 AM PT and participate in a keynote panel discussion titled 'Artificial Irrelevance? How Canadian Techs are Building Intelligence and Purpose into AI Solutions' at 8:30 AM. The panel will be moderated by Brady Fletcher, President of Roth Canada.
Both Dr. Dobranowski and Anthony Lam, CFO of HEALWELL, will attend the conference and conduct in-person 1x1 meetings with investors. The event provides an opportunity for HEALWELL to showcase its vision of revolutionizing healthcare through AI-driven preventative care and engage with the investment community.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) has announced that its subsidiary, BioPharma Services Inc., is expanding into late-stage patient trials by integrating Canadian Phase Onward (CPO). This strategic move transforms BioPharma into a full-service Contract Research Organization (CRO), capable of managing clinical trials across all phases of drug development. The integration also involves incorporating HEALWELL's AI and data science capabilities to enhance research, disease detection, and patient identification.
Key benefits include:
- Expanded capabilities across all clinical trial stages
- Increased patient access through WELL Health's populations
- Enhanced research infrastructure with a robust referral network
- Integration of AI for improved patient identification and trial efficiency
BioPharma has completed over 2,200 clinical trials with approximately 250 pharma clients globally, including 4 of the top 25 largest pharmaceutical companies.
HEALWELL AI Inc.'s subsidiary, Pentavere, has been nominated for a 2024 Prix Galien award in the Best Digital Health Startup category. This marks Pentavere's third nomination in three years. The Prix Galien is considered the most prestigious honor in the life sciences and pharmaceutical industry. To date, over 1 million patients have benefited from Pentavere's DARWEN™ AI system.
Pentavere will be presenting at several upcoming medical conferences, showcasing the capabilities of its DARWEN™ AI platform in generating real-world evidence and identifying patient cohorts with unmet needs. These conferences include the 46th ESPEN Congress, 66th ASTRO Annual Meeting, United European Gastroenterology Week, and the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting.
WELL Health's OceanMD and HEALWELL's Intrahealth have announced a strategic partnership to integrate OceanMD's leading eReferral system across Intrahealth's global network. This collaboration aims to enhance digital interoperability, streamline healthcare processes, and improve patient access to care. OceanMD's platform currently handles over 120,000 eReferrals and eConsults monthly and has secured contracts with Ontario, British Columbia, and Nova Scotia for provincial deployments.
The integration will allow healthcare providers to send, receive, and manage eReferrals directly from their EMR, simplifying workflows and improving patient care. This partnership is expected to reduce administrative burdens, enhance provider efficiency, and offer patients better access to their health data.
WELL Health's OceanMD and HEALWELL's Intrahealth have announced a strategic partnership to integrate OceanMD's eReferral system across Intrahealth's global network. This collaboration aims to enhance digital interoperability, streamline healthcare processes, and improve patient access to care. OceanMD's platform currently handles over 120,000 eReferrals and eConsults monthly and has secured contracts with Ontario, British Columbia, and Nova Scotia for provincial deployments.
The integration will allow healthcare providers to send, receive, and manage eReferrals directly from their EMR, simplifying workflows and improving patient care. This partnership is expected to reduce administrative burdens, enhance provider efficiency, and offer patients better access to their health data.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) reported record quarterly revenue of $5.44 million in Q2-2024, a 205% increase from Q2-2023. The company also achieved net income of $2.54 million, compared to a loss of $9.81 million in Q2-2023. This turnaround was primarily due to settling past liabilities and successful equity financing of $20 million.
Key highlights include:
- Adjusted Gross Profit of $3.76 million, up 669% year-over-year
- Adjusted Gross Margin of 69%, up from 27% in Q2-2023
- Cash balance of $19.82 million as of June 30, 2024
- Acquisition of BioPharma Services Inc. and Verosource Solutions Inc. on July 1, 2024
HEALWELL aims to reach a revenue run-rate approaching $100 million by year-end, driven by M&A activities and increased adoption of its AI-powered healthcare solutions.